ES2076142T3 - Peptidos para el diagnostico de anticuerpos para htlv-iii, su preparacion y uso. - Google Patents

Peptidos para el diagnostico de anticuerpos para htlv-iii, su preparacion y uso.

Info

Publication number
ES2076142T3
ES2076142T3 ES87300961T ES87300961T ES2076142T3 ES 2076142 T3 ES2076142 T3 ES 2076142T3 ES 87300961 T ES87300961 T ES 87300961T ES 87300961 T ES87300961 T ES 87300961T ES 2076142 T3 ES2076142 T3 ES 2076142T3
Authority
ES
Spain
Prior art keywords
recombinant protein
recovering
refractile
recombinant
htlv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87300961T
Other languages
English (en)
Inventor
Richard M Thorn
Dante Juan Marciani
Chung-Ho Hung
Gerald A Beltz
William A Haseltine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Biotech Corp
Original Assignee
Cambridge Biotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/825,597 external-priority patent/US4753873A/en
Application filed by Cambridge Biotech Corp filed Critical Cambridge Biotech Corp
Application granted granted Critical
Publication of ES2076142T3 publication Critical patent/ES2076142T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/42—Introducing metal atoms or metal-containing groups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Abstract

CIERTOS FRAGMENTOS DE PEPTIDOS DEL VIRUS DE LA LEUCEMIA T HUMANA (LINFOTROPICO) (HTLV-III) SON PARTICULARMENTE INMUNORREACTIVOS FRENTE A LOS ANTICUERPOS DE LA HTLV-III, Y PUEDEN, POR LO TANTO, APLICARSE PARA PRUEBAS DE INMUNODIAGNOSTICO PARA DETECTAR ANTICUERPOS DE LA HTLV-III.
ES87300961T 1986-02-03 1987-02-03 Peptidos para el diagnostico de anticuerpos para htlv-iii, su preparacion y uso. Expired - Lifetime ES2076142T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/825,597 US4753873A (en) 1986-02-03 1986-02-03 Peptides for the diagnosis of HTLV-III antibodies, their preparation and use
US06/911,455 US4734362A (en) 1986-02-03 1986-09-25 Process for purifying recombinant proteins, and products thereof

Publications (1)

Publication Number Publication Date
ES2076142T3 true ES2076142T3 (es) 1995-11-01

Family

ID=27124926

Family Applications (2)

Application Number Title Priority Date Filing Date
ES87300960T Expired - Lifetime ES2060594T3 (es) 1986-02-03 1987-02-03 Proceso para purificar proteinas recombinantes y uso de productos de las mismas.
ES87300961T Expired - Lifetime ES2076142T3 (es) 1986-02-03 1987-02-03 Peptidos para el diagnostico de anticuerpos para htlv-iii, su preparacion y uso.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES87300960T Expired - Lifetime ES2060594T3 (es) 1986-02-03 1987-02-03 Proceso para purificar proteinas recombinantes y uso de productos de las mismas.

Country Status (12)

Country Link
US (1) US4734362A (es)
EP (3) EP0233045B1 (es)
JP (4) JP2608081B2 (es)
AT (2) ATE109513T1 (es)
AU (2) AU601175B2 (es)
DE (2) DE3751310T2 (es)
DK (2) DK520187D0 (es)
ES (2) ES2060594T3 (es)
GR (1) GR3017187T3 (es)
IE (3) IE940558L (es)
OA (2) OA08762A (es)
WO (2) WO1987004726A1 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956273A (en) * 1985-10-24 1990-09-11 Southwest Foundation For Biomedical Research Synthetic peptides and method of use for diagnosis and vaccination for AIDS and ARC
US5075211A (en) * 1986-03-26 1991-12-24 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
EP0525828A3 (en) * 1986-08-01 1993-02-24 Repligen Corporation Recombinant polypeptides and their uses, including assay for aids virus
NZ221440A (en) * 1986-08-20 1991-11-26 Genetic Systems Corp Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections
US5166050A (en) * 1986-08-20 1992-11-24 Bristol-Myers Squibb Company Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections
US5179199A (en) * 1986-10-20 1993-01-12 Genzyme Corporation Protein purification
DE3637253A1 (de) * 1986-11-03 1988-05-05 Behringwerke Ag Latex-agglutinations-verfahren zum nachweis von anti-streptokokken-desoxyribonuclease b
US4940456A (en) * 1987-02-10 1990-07-10 Dan Sibalis Electrolytic transdermal delivery of proteins
WO1988008428A1 (en) * 1987-04-28 1988-11-03 Amgen Inc. Method for purifying granulocyte/macrophage colony stimulating factor
US4921787A (en) * 1987-05-01 1990-05-01 Cambridge Bioscience Corporation Detection of antibodies to human immunodeficiency virus by agglutination of antigen coated latex
DE3787654D1 (de) * 1987-12-23 1993-11-04 Immuno Ag Zellulaere amphipatische proteine in aggregierten formen und verfahren zur herstellung und reinigung diese proteine.
US6214537B1 (en) 1988-01-27 2001-04-10 Biochem Immunosystems, Inc. Synthetic peptides and mixtures thereof for detecting HIV antibodies
US6218102B1 (en) 1988-01-27 2001-04-17 Biochem Immunosystems, Inc. Synthetic peptides and mixtures thereof for detecting HIV antibodies
US5241047A (en) * 1988-12-08 1993-08-31 Biochem Pharma Inc. Synthetic peptides and mixtures thereof for detecting HIV antibodies
US6210874B1 (en) 1988-01-27 2001-04-03 Biochem Immunosystems, Inc. Synthetic peptides and mixtures thereof for detecting HIV antibodies
AU3754389A (en) * 1988-05-31 1990-01-05 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
DE3839020A1 (de) * 1988-11-18 1990-05-23 Roehm Gmbh Fixierung von proteinen an festen traegern
GB8828097D0 (en) * 1988-12-01 1989-01-05 Wellcome Found Peptides
GB8828098D0 (en) * 1988-12-01 1989-01-05 Wellcome Found Peptides
EP0699758B1 (en) * 1988-12-13 2002-07-24 President And Fellows Of Harvard College Prototype felv isolates for use in disease models and vaccines
US5270030A (en) * 1988-12-29 1993-12-14 Bio-Technology General Corp. Fibrin binding domain polypeptide and method of producing
US5679320A (en) * 1988-12-29 1997-10-21 Bio-Technology General Corp. Fibrin binding domain polypeptides and uses and methods of producing same
US5858646A (en) * 1989-02-23 1999-01-12 University Of Ottawa Modified HIV-pol polypeptide having immunological activity for use as diagnostic reagent
US5552302A (en) * 1989-04-24 1996-09-03 Promega Corporation Methods and compositions for production of human recombinant placental ribonuclease inhibitor
US5180820A (en) * 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
US5243027A (en) * 1990-02-26 1993-09-07 Unitika, Ltd. Method of preparing angiotensin converting enzyme inhibitors
US5530100A (en) * 1990-05-07 1996-06-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Methods for purification of recombinantly produced proteins
US5258496A (en) * 1990-07-10 1993-11-02 Scios Nova Inc. Isolation and purification of lung surfactant protein
US5235041A (en) * 1990-12-28 1993-08-10 Protein Polymer Technologies, Inc. Purification of structurally ordered recombinant protein polymers
US5389529A (en) * 1991-06-12 1995-02-14 Regeneron Pharmaceuticals, Inc. Modified lamβ signal sequence and processes for producing recombinant neurotrophins
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
CA2099967A1 (en) * 1992-07-07 1994-01-08 Hidetsune Tamaoki Process for recovering peptides expressed as fusion proteins
PT700445E (pt) * 1993-06-04 2002-07-31 Whitehead Biomedical Inst Proteinas de stress e suas utilizacoes
WO1995016040A2 (en) * 1993-12-10 1995-06-15 The Canadian Red Cross Society Immunofluorescence assay for the detection of antibodies using recombinant antigens in insoluble form
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
FR2726576B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Production de peptides analogues de peptides hydrophobes, peptide recombinant, sequence d'adn correspondante
JPH1123530A (ja) * 1996-03-28 1999-01-29 Fmc Corp 電気泳動技術に用いる安定な変性剤及びその使用方法
US7157089B1 (en) * 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
US5993627A (en) * 1997-06-24 1999-11-30 Large Scale Biology Corporation Automated system for two-dimensional electrophoresis
US6068993A (en) * 1997-07-02 2000-05-30 Biobras Sa Vector for expression of heterologous protein and methods for extracting recombinant protein and for purifying isolated recombinant insulin
WO1999055715A2 (en) 1998-04-28 1999-11-04 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
CN1367875A (zh) * 1999-07-08 2002-09-04 斯特思吉生物技术公司 活体外th1一样反应的诱导方法
JP2003513022A (ja) * 1999-10-27 2003-04-08 インノジェネティクス・エヌ・ブイ 天然に似たコンフォメーションを有する酸化還元の可逆的なｈｃｖタンパク質
SE9904272D0 (sv) * 1999-11-25 1999-11-25 Amersham Pharm Biotech Ab A method for selective removal of a substance from samples containing compounds having nucleic acid structure
US6964851B2 (en) * 1999-12-07 2005-11-15 Stressgen Biotechnologies Corp. Compositions and methods for detecting stress-inducible proteins
ATE438408T1 (de) * 2000-01-14 2009-08-15 Whitehead Biomedical Inst Induktion zytotoxischer lymphozyten durch hitzeschockprotein-fusionsproteine hängt von der atp-bindungsdomäne in hsp ab und is cd4+ unabhängig
WO2002000242A2 (en) * 2000-06-26 2002-01-03 Stressgen Biotechnologies Corporation Human papilloma virus treatment
WO2002004512A2 (en) * 2000-07-10 2002-01-17 Diosynth Rtp, Inc. Purification of human troponin i
IL157251A0 (en) * 2001-02-05 2004-02-19 Stressgen Biotechnologies Corp Hepatitis b virus treatment
US20030105017A1 (en) * 2001-07-10 2003-06-05 Gregory Conn Purification of human Troponin I
US6713272B2 (en) * 2001-09-19 2004-03-30 The United States Of America As Represented By The Secretary Of The Navy Attachment of biomolecules to hydrophobic surfaces
WO2003078453A1 (en) * 2002-03-15 2003-09-25 Wyeth Holdings Corporation Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
WO2004048530A2 (en) * 2002-11-22 2004-06-10 Carnegie Mellon University Compositions and methods for the reversible capture of biomolecules
CA2511228A1 (en) * 2002-12-20 2004-07-08 Mitsubishi Pharma Corporation Method of protecting thiol group of protein
NL1025149C2 (nl) * 2003-12-30 2005-07-04 Univ Delft Tech Werkwijze voor het produceren van een fermentatieproduct uit een organisme.
EP1851544A4 (en) * 2005-02-18 2008-12-10 Univ Carnegie Mellon COMPOSITIONS AND METHODS FOR REVERSIBLE INFLAMMATION OF BIOMOLECULES
IES20050816A2 (en) * 2005-12-06 2007-05-16 Trinity Res Ltd A method for preparing microbeads for use in an assay for determining the presence of antibodies to human immunodeficiency virus in a sample
JP5566104B2 (ja) 2006-07-14 2014-08-06 ジェネンテック， インコーポレイテッド 組み換えタンパク質の再折り畳み
US20110044968A1 (en) * 2008-03-10 2011-02-24 Pharmal N Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
WO2011109556A2 (en) 2010-03-04 2011-09-09 Pfenex Inc. Method for producing soluble recombinant interferon protein without denaturing
PL394619A1 (pl) * 2011-04-19 2012-10-22 Miedzynarodowy Instytut Biologii Molekularnej I Komórkowej Sposób proteolizy, peptydaza, kompozycja do stosowania jako srodek bakteriostatyczny lub bakteriobójczy, zestaw oraz zastosowania aktywnej formy LytM z S. aureus lub jej pochodnej
EP3918340A1 (en) * 2019-01-30 2021-12-08 Regeneron Pharmaceuticals, Inc. Method of characterization of visible and/or sub-visible particles in biologics

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4021303A (en) * 1972-11-10 1977-05-03 Dai-Nippon Sugar Manufacturing Co., Ltd. Method for treatment of microorganisms
BE821053A (fr) * 1974-08-01 1975-04-14 Produit pour diagnostic par determination immunochimique
GB1549069A (en) * 1976-12-10 1979-08-01 Erba Farmitalia Enzyme linked immunoassay
US4168262A (en) * 1978-03-13 1979-09-18 Cornell Research Foundation, Inc. Anhydride modified microbial protein having reduced nucleic acid levels
US4551502A (en) * 1979-09-14 1985-11-05 Howell Bobby A Macromolecular complexes of amidocarbonylic water-soluble polymers and square platinous and equivalent organometallics
US4350764A (en) * 1980-03-10 1982-09-21 The Regents Of The University Of California Microbiological synthesis of beta endorphin
US4348479A (en) * 1980-08-18 1982-09-07 Cornell Research Foundation, Inc. Recovery of proteinaceous material having reduced nucleic acid levels
US4427580A (en) * 1982-09-01 1984-01-24 Cornell Research Foundation, Inc. Method for separation and recovery of proteins and nucleic acids from nucleoproteins using water destructuring salts
US4599197A (en) * 1982-12-22 1986-07-08 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511503A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4518526A (en) * 1982-12-22 1985-05-21 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
GR79124B (es) * 1982-12-22 1984-10-02 Genentech Inc
US4512922A (en) * 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
JPS59224565A (ja) * 1983-04-28 1984-12-17 Morinaga Milk Ind Co Ltd 抗原検出用試薬
GB8324800D0 (en) * 1983-09-15 1983-10-19 Pasteur Institut Antigens
JPS6061534A (ja) * 1983-09-16 1985-04-09 Kyowa Hakko Kogyo Co Ltd 成人ｔ細胞白血病ウイルス抗原ペプチド
US4701416A (en) * 1983-12-09 1987-10-20 Cetus Corporation Feline leukemia virus vaccine plasmids for fusion protein of the gp70 envelope protein of FELV
US4520113A (en) * 1984-04-23 1985-05-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions
IE58321B1 (en) * 1984-04-23 1993-09-08 Us Health Isolation of proteins of HTLV-III, serological detection of antibodies to HTLV-III in sera of patients with aids and pre-aids conditions, and detection of HTLV-III infection bi/immuno-assays using HTLV-III infection by immuno-assays using HTLV-III and its proteins
DE3432196A1 (de) * 1984-09-01 1986-03-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Neues mechanisches aufschlussverfahren von bakterienzellen zur isolierung von rekombinant hergestellten peptiden
KR930000189B1 (ko) * 1984-10-18 1993-01-11 앵스뛰띠 빠스뙤르 임파선증과 후천성 면역 결핍증 바이러스의 항원을 제조하는 방법 및 이 항원에 대한 항체의 생산 방법
CA1341482C (en) * 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
US4725669A (en) * 1984-11-09 1988-02-16 President And Fellows Of Harvard College Assay for detecting infection by human T-cell lymphotropic virus-III
ATE138100T1 (de) * 1984-12-24 1996-06-15 Genentech Inc Fusionen von aids-verwandten polypeptiden
US4774175A (en) * 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
IE64785B1 (en) * 1985-04-08 1995-09-06 Genetic Systems Corp Expression of immunologically reactive viral proteins
FR2580177B2 (fr) * 1985-04-15 1989-06-02 Pasteur Institut Antigenes apparentes a la glycoproteine d'enveloppe du virus du sida, notamment precurseurs de cette glycoproteine, procedes d'obtention de ces antigenes et moyens mis en oeuvre dans ces procedes, applications de ces antigenes a la preparation de compositions immunogenes ou pour le diagnostic du sida ou des affections qui lui sont apparentees
DK171119B1 (da) * 1985-04-19 1996-06-17 Hoffmann La Roche AIDS-viruskappeprotein, ekspressionsvektor bærende viruskappeproteinet, transformanter transformeret med ekspressionsvektoren, fremgangsmåde til fremstilling af viruskappeproteinet, fremgangsmåde til detektion af AIDS-antistoffer, fremgangsmåde til bestemmelse af AIDS-virus, vaccine mod AIDS, antistoffer mod viruskappeproteinet samt anvendelse af dette til fremstilling af en vaccine og til testnin
KR910002374B1 (ko) * 1985-04-29 1991-04-20 제네틱 시스템즈 코포레이션 Aids 관련질병의 검출을 위한 합성항원
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
US4661445A (en) * 1985-05-24 1987-04-28 Saxinger W Carl Competitive ELISA for the detection of HTLV-III antibodies
GR862412B (en) * 1985-09-25 1987-01-23 Oncogen Vaccines and immuinoassays for acquired immune deficiency syndrome

Also Published As

Publication number Publication date
IE870281L (en) 1987-08-03
DE3750301D1 (de) 1994-09-08
AU7022787A (en) 1987-08-25
DK520187A (da) 1987-10-02
ATE109513T1 (de) 1994-08-15
DE3750301T2 (de) 1995-03-09
ES2060594T3 (es) 1994-12-01
JPH1081700A (ja) 1998-03-31
DK520187D0 (da) 1987-10-02
JP2670039B2 (ja) 1997-10-29
JPS63502957A (ja) 1988-11-02
EP0233044A2 (en) 1987-08-19
OA08687A (en) 1989-03-31
IE940558L (en) 1987-08-03
EP0233044B1 (en) 1994-08-03
EP0233045A3 (en) 1989-05-03
AU601175B2 (en) 1990-09-06
JP2786436B2 (ja) 1998-08-13
EP0596459A3 (en) 1994-06-01
JP2733059B2 (ja) 1998-03-30
EP0596459A2 (en) 1994-05-11
JPH09119930A (ja) 1997-05-06
DE3751310D1 (de) 1995-06-29
WO1987004728A1 (en) 1987-08-13
EP0233045A2 (en) 1987-08-19
IE64902B1 (en) 1995-09-20
AU605477B2 (en) 1991-01-17
IE81121B1 (en) 2000-03-22
WO1987004726A1 (en) 1987-08-13
EP0233044A3 (en) 1990-07-25
JP2608081B2 (ja) 1997-05-07
JPS63502958A (ja) 1988-11-02
AU7081987A (en) 1987-08-25
DK520087D0 (da) 1987-10-02
IE870282L (en) 1987-08-03
ATE123063T1 (de) 1995-06-15
GR3017187T3 (en) 1995-11-30
DK520087A (da) 1987-10-02
EP0233045B1 (en) 1995-05-24
DE3751310T2 (de) 1996-02-15
OA08762A (en) 1989-03-31
US4734362A (en) 1988-03-29

Similar Documents

Publication Publication Date Title
ES2076142T3 (es) Peptidos para el diagnostico de anticuerpos para htlv-iii, su preparacion y uso.
Milstein The disulphide bridges of immunoglobulin κ-chains
Shoji et al. Complete amino acid sequence of the catalytic subunit of bovine cardiac muscle cyclic AMP-dependent protein kinase.
DK60586A (da) Inhibin isoleret fra ovariefollikelvaeske og fremgangsmaade til isolering og rensning af inhibin
EP0331126A3 (en) Process for the determination of a protein according to the principle of fluorescense polarisation immunoassay
EP0379949A3 (de) Verfahren zur Bestimmung von HIV-Antikörpern
Schmidt et al. Partial amino acid sequence of the heavy and light chains of botulinum neurotoxin type A
DE68928704T2 (de) Gruppe von getrennten peptiden
NO900758L (no) Fremgangsmaate for fremstilling av hybridprotein.
Yamashiro et al. Isomeric dimers of oxytocin
Lay The terminal groups of the human and bovine [gamma]-globulin

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 233045

Country of ref document: ES